Drug class in one race
LAG-3 drugs for Non-Small Cell Lung Cancer
2 tracked LAG-3 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the LAG-3 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 31 Phase 2
Head-to-head evidence: HLX26 vs Relatlimab